Proc. Natl. Acad. Sci. USA
High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells.
Mathews Griner, L.A., Guha. R., Shinn. P., Young, R.M., Keller,J.M., Liu, D., Goldlust, I.S., Yasgar, A., McKnight, C., Boxer, M.B., Duveau, D.Y., Jiang, J.K., Michael, S., Mierzwa, T., Huang, W., Walsh, M.J., Mott, B.T., Patel, P., Leister, W., Maloney, D.J., Leclair, C.A., Rai, G., Jadhav, A., Peyser, B.D., Austin, C.P., Martin, S.E., Simeonov, A., Ferrer, M., Staudt, L.M. and Thomas, C.J.
Notes: To avoid the trial-and-error methodology involved in developing multidrug treatments, the authors designed and tested a platform for high-throughput combination screening to easily discover pairs of small molecules that could then be explored further. Cell lines tested were dispensed at 1,000 cells per well in 5µl of medium into a 1,536-well plate either directly to compound matrix plates or adding 23nl of bortezomib and library compounds to the cells. After a 48-hour incubation, 3µl of CellTiter-Glo® Luminescent Cell Viability Assay reagent was dispensed and luminescence read to assess cell proliferation. (4209)
Expand Full Notes »